M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 4, 2013, Pages 552-566

  Ferretti, Michela ^a   Fabbiano, Cinzia ^a   Bari, Maria Di ^a   Conte, Claudia ^a   Castigli, Emilia ^c   Sciaccaluga, Miriam ^c   Ponti, Donatella ^a   Ruggieri, Paola ^a   Raco, Antonino ^d   Ricordy, Ruggero ^b   Calogero, Antonella ^a   Tata, Ada Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; Arecaidine; Cell cycle; Glioblastoma; M2 muscarinic receptors; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; ARECAIDINE; ARECOLINE; DRUG DERIVATIVE; MUSCARINIC AGENT; MUSCARINIC M2 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; GLIOBLASTOMA; HUMAN; IC 50; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARECOLINE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOBLASTOMA; HUMANS; INHIBITORY CONCENTRATION 50; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, MUSCARINIC M2; SIGNAL TRANSDUCTION;

EID: 84877019142     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12038     Document Type: Article

References (46)

1. Eglen RM. Muscarinic receptor subtype pharmacology and physiology. Prog Med Chem. 2005; 43: 105-36.
2. Cohen RI, Molina-Holgado E, Almazan G. Carbachol stimulates c-fos expression and proliferation in oligodendrocyte progenitors. Mol Brain Res. 1996; 43: 193-201.
3. Larocca JN, Alzman G. Acetylcholine agonists stimulate mitogen-activated protein kinase in oligodendrocyte progenitors by muscarinic receptors. J Neurosci. 1997; 50: 743-54.
4. Loreti S, Ricordy R, De Stefano ME, et al. Acetylcholine inhibits cell cycle progression in rat Schwann cells by activation of the M2 receptor subtype. Neuron Glia Biol. 2007; 3: 269-79.
5. Ragheb F, Molina-Holgado E, Cui Q, et al. Pharmacological and functional characterization of muscarinic receptor subtypes in developing oligodendrocytes. J Neurochem. 2001; 77: 1396-406.
6. De Angelis F, Bernardo A, Magnaghi V, et al. Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation and differentiation. Develop Neurobiol. 2012; 72: 713-28.
7. Loreti S, Vilarò MT, Visentin S, et al. Rat Schwann Cells express M1-M4 muscarinic receptor subtypes. J Neurosci Res. 2006; 84: 97-105.
8. Ma W, Li BS, Zhang L, et al. Signaling cascades implicated in muscarinic regulation of proliferation of neural stem and progenitor cells. Drug News Perspect. 2004; 17: 258-66.
9. Zhou C, Wen ZX, Shi DM, et al. Muscarinic acetylcholine receptors involved in the regulation of neural stem cell proliferation and differentiation in vitro. Cell Biol Inter. 2004; 28: 63-7.
10. Felder CC, Baymaster FP, Ward J, et al. Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem. 2000; 43: 4333-53.
11. Wang H, NG K, Hayes D, et al. Decreased amphetamine-induced locomotion and improved latent inhibition in mice mutant for the M5 muscarinic receptor gene found in human 15q schizophrenia region. Neuropsychopharmacol. 2005; 29: 2126-39.
12. Tata AM. Muscarinic Acetylcholine receptors: new potential therapeutic targets in antinociception and in cancer therapy. Rec Patents in CNS Drug Discov. 2008; 3: 1-10.
13. Hulme HC, Birdsall NJM, Buckley NJ. Muscarinic receptor subtypes. Ann Rev Pharmacol Toxicol. 1990; 30: 633-73.
14. Cui QL, Fogle E, Almazan G. Muscarinic acetylcholine receptors mediate survival through Src-like tyrosine kinase and PI3K/AKT pathways. Neurochem Int. 2006; 48: 383-93.
15. Williams CL, Lennon A. Activation of muscarinic acetylcholine receptors inhibits cell cycle progression of small cell lung carcinoma. Cell Regulation. 1991; 2: 373-81.
16. Rayford W, Noble MJ, Austenfeld MA, et al. Muscarinic cholinergic receptors promote growth of human prostate cancer cells. Prostate. 1997; 30: 160-6.
17. Frucht H, Jensen RT, Dexter D, et al. Human colon cancer cell proliferation mediated by the M3 muscarinic cholinergic receptor. Clinical Cancer Res. 1999; 5: 2532-9.
18. Oppitz M, Möbus V, Brock S, et al. Muscarinic receptors in cell lines from ovarian carcinoma: negative correlation with survival of patients. Gynecologic Oncol. 2002; 85: 159-64.
19. Song P, Sekhon HS, Lu A, et al. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res. 2007; 67: 3936-44.
20. Boss A, Oppitz M, Drews U. Muscarinic cholinergic receptors in the human melanoma cell line SK-Mel 28: modulation of chemotaxis. Clin Exp Dermatol. 2005; 30: 557-64.
21. Rimmaudo LE, De La Torre E, Sacerdote de Lustig E, et al. Muscarinic receptors are involved in LMM3 tumor cells proliferation and angiogenesis. Bioch Bioph Res Com. 2005; 334: 1359-64.
22. Jiménez E, Montiel M. Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells. J Cell Physiol. 2005; 204: 678-86.
23. Oppitz M, Busch G, Garbe C, et al. Distribution of muscarinic receptor subtype M3 in melanomas and their metastases. J Cutan Pathol. 2008; 35: 809-15.
24. Song P, Harmanjatider S, Sekhon S, et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res. 2003; 63: 214-21.
25. Murphy S, Pearce B, Morrow C. Astrocytes have both M1 and M2 muscarinic receptor subtypes. Brain Res. 1986; 364: 177-80.
26. Guizzetti M, Costa P, Peters J, et al. Acetylcholine as a mitogen: muscarinic receptor-mediated proliferation of rat astrocytes and human astrocytoma cells. Europ J Pharmacol. 1996; 297: 265-73.
27. Tata AM, Calogero A. Muscarinic receptors and cancer: possible implications in tumors of the nervous system. Curr Trends in Neurol. 2010; 4: 23-31.
28. Ferretti M, Fabbiano C, Di Bari M, et al. M2 muscarinic receptors inhibit cell proliferation in human glioblastoma cell lines. Life Sci. 2012; 91: 1134-37.
29. Calogero A, Porcellini A, Lombari V, et al. Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression. Cancer Cell Int. 2011; 2: 11-5.
30. Huang JL, McLeish MJ. High-performance liquid chromatographic determination of the alkaloids in betel nut. J Chromatogr. 1989; 475: 447-50.
31. Barlow RB, Weston-Smith P. The relative potencies of some agonists at M2 muscarinic receptors in guinea pig ileum, atria and bronchi. Br J Pharmacol. 1985; 85: 437-40.
32. Mosman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55-63.
33. Ridet A, Guillouf C, Duchaud E, et al. Deregulated apoptosis is a hallmark of Fanconi anemia syndrome. Canc Res. 1997; 57: 1722-30.
34. Darzynkiewicz Z, Bruno S, Del Bino G, et al. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992; 13: 795-808.
35. Calogero A, Lombari V, De Gregorio G, et al. Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma. Cancer Cell Int. 2004; 4: 1-12.
36. Bordey A, Sontheimer H, Drouslard J. Muscarinic activation of BK channels induces membrane oscillations in glioma cells and leads to inhibition of cell migration. J Membrane Biol. 2000; 176: 31-40.
37. Hambardzamyan D, Squatrito M, Carbajal E, et al. Glioma formation, cancer stem cells, and AKT signaling. Stem Cell Rep. 2008; 4: 203-10.
38. West KA, Brognard J, Clark AS, et al. Rapid AKT activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest. 2003; 111: 81-90.
39. Holland EC, Celestino J, Dai C, et al. Combined activation of Ras and AKT in neural progenitors induces glioblastoma formation in mice. Nature Gen. 2000; 25: 55-7.
40. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007; 1773: 1263-84.
41. Castigli E, Arcuri C, Giovagnoli L, et al. Interleukin-1beta induces apoptosis in GL15 glioblastoma-derived human cell lines. Am J Physiol Cell Physiol. 2000; 279: 2043-9.
42. Castigli E, Sciaccaluga M, Schiavoni G, et al. GL15 and U251 glioblastoma-derived human cell lines are peculiarly susceptible to induction of mitotic death by very low concentrations of okadaic acid. Oncol Rep. 2006; 15: 463-70.
43. Lu J, Kovach JS, Johnson F, et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci USA. 2009; 106: 11697-702.
44. Cheng K, Samimi R, Xie G, et al. Acetylcholine release by human colon cancer cells mediates autocrine stimulation of cell proliferation. Am J Physiol Gastrointest Liver Physiol. 2008; 295: 591-7.
45. Thiers CA, Barbosa JL, Pereira BD, et al. Autonomic dysfunction and anti-M2 and β1 receptor antibodies I Chagas disease patients. Arq Bas Cardiol. 2012; 99: 732-9.
46. Shah N, Khurana S, Cheng K, et al. Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol. 2009; 296: 221-32.